SG pharma firms delay US expansion amidst tariff clarifications: Minister Gan

The new tariffs were put on hold so companies could negotiate exemptions with US officials.

Numerous drug companies are pausing their plans to expand in the US until the American government clarifies if they will be exempted from new tariffs, Minister Gan Siow Huang told the Parliament on Tuesday.

The new tariffs were put on hold so companies could negotiate exemptions with US officials.

Specifically, many Singapore-based pharmaceutical companies intending to build or enlarge their US facilities need further guidance to confirm their projects will qualify for that exemption.

Gan mentioned that Singapore is currently negotiating a special, favourable tariff agreement with the US for its drug exports.

She clarified that the majority of what Singapore exports to the US in this sector is active pharmaceutical ingredients, not ready-to-use medications like tablets or capsules.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia